Pinter, Matthias https://orcid.org/0000-0002-7260-532X
Scheiner, Bernhard
Peck-Radosavljevic, Markus
Clinical trials referenced in this document:
Documents that mention this clinical trial
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
https://doi.org/10.1136/gutjnl-2020-321702
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults
https://doi.org/10.1136/gutjnl-2023-331695
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba4008
Documents that mention this clinical trial
Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.
https://doi.org/10.1200/jco.2023.41.16_suppl.4002
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
https://doi.org/10.1136/gutjnl-2020-321702
Documents that mention this clinical trial
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
https://doi.org/10.1136/gutjnl-2020-321702